Table 3 Survival outcomes in trials of treating SCLC.
Treatment | Trials | n | Enrolled patients with stage III | 24-month PFS | mPFS | 24-month OS | mOS |
|---|---|---|---|---|---|---|---|
CCRT | JCOG910426 | n = 114 | 57%IIIA+37%IIIB | 30% | 12 | 54.4% | 27.2 |
Convert (twice daily)1 | n = 274 | 80%III | 45% | 15.4 | 56% | 30 | |
CCRT+ anti-PD-1/PD-L1 therapy | Pembroli-zumab with CCRT7 | n = 40 | 83%III+2%IV | 45% | 19.7 | 65.8% | 39.5 |
Durvalumab with CCRT8 | n = 50 | 54%IIIA+24%IIIB | 42.0% | 14.4 | 67.8% | NRb | |
CCRT followed by immuno-therapy | ETOP/IFCT 4-12 STIMULI21 | Nivo-lumab & Ipilimu-mab n = 78 | 33.3%IIIA + 51.3%IIIB | 43.2% | 10.7 | 62.9% | NRb |
placebo n = 75 | 36%IIIA+48%IIIB | 40.3% | 14.5 | 66.4% | 32.1 | ||
ADRIATIC9 | Durva-lumab n = 264 | 87.5%III | 46.2% | 16.6 | 68.0% | 55.9 | |
Placebo n = 266 | 87.2% III | 34.2% | 9.2 | 58.5% | 33.4 | ||
Immunotherapy followed by surgery or radiotherapy (our study) | ITTa n = 40 | 95%III (40%IIIA + 40%IIIB + 15%IIIC) | 42.5% | 16.2 | 75.4% | NRb | |
Surgery n = 21 | 95.2%III (57%IIIA + 28.6%IIIB + 9.5%IIIC) | 61.9% | NRb | 85.7% | NRb | ||
Radio-therapy n = 15 | 92.9%III (14.3%IIIA + 50%IIIB + 28.6%IIIC) | 14.3% | 13.59 | 42.9% | 20.2 | ||
